Barinthus Biotherapeutics (NASDAQ:BRNS) Announces Quarterly Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) announced its quarterly earnings results on Thursday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.13, FiscalAI reports.

Barinthus Biotherapeutics Trading Down 6.0%

Shares of BRNS stock opened at $0.64 on Thursday. The stock has a market capitalization of $26.09 million, a price-to-earnings ratio of -0.39 and a beta of -0.63. Barinthus Biotherapeutics has a 12-month low of $0.56 and a 12-month high of $2.92. The stock’s 50-day moving average price is $0.67 and its 200-day moving average price is $0.90.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Renaissance Technologies LLC increased its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 143,100 shares of the company’s stock after buying an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned about 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.20% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.